» Articles » PMID: 28830373

Statistical Methods for Elimination of Guarantee-time Bias in Cohort Studies: a Simulation Study

Overview
Publisher Biomed Central
Date 2017 Aug 24
PMID 28830373
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Aspirin has been considered to be beneficial in preventing cardiovascular diseases and cancer. Several pharmaco-epidemiology cohort studies have shown protective effects of aspirin on diseases using various statistical methods, with the Cox regression model being the most commonly used approach. However, there are some inherent limitations to the conventional Cox regression approach such as guarantee-time bias, resulting in an overestimation of the drug effect. To overcome such limitations, alternative approaches, such as the time-dependent Cox model and landmark methods have been proposed. This study aimed to compare the performance of three methods: Cox regression, time-dependent Cox model and landmark method with different landmark times in order to address the problem of guarantee-time bias.

Methods: Through statistical modeling and simulation studies, the performance of the above three methods were assessed in terms of type I error, bias, power, and mean squared error (MSE). In addition, the three statistical approaches were applied to a real data example from the Korean National Health Insurance Database. Effect of cumulative rosiglitazone dose on the risk of hepatocellular carcinoma was used as an example for illustration.

Results: In the simulated data, time-dependent Cox regression outperformed the landmark method in terms of bias and mean squared error but the type I error rates were similar. The results from real-data example showed the same patterns as the simulation findings.

Conclusions: While both time-dependent Cox regression model and landmark analysis are useful in resolving the problem of guarantee-time bias, time-dependent Cox regression is the most appropriate method for analyzing cumulative dose effects in pharmaco-epidemiological studies.

Citing Articles

Effect of choline alfoscerate in older adult patients with dementia: an observational study from the claims data of national health insurance.

Duong K, Jung H, Lee H, Moon Y, Lee S, Yang B BMC Geriatr. 2024; 24(1):951.

PMID: 39548376 PMC: 11566286. DOI: 10.1186/s12877-024-05531-y.


Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study.

Doi H, Matsuo Y, Kishi N, Ogura M, Mitsuyoshi T, Ueki N Target Oncol. 2024; 20(1):161-169.

PMID: 39511126 DOI: 10.1007/s11523-024-01105-5.


Addressing immortal time bias in precision medicine: Practical guidance and methods development.

Weymann D, Krebs E, Regier D Health Serv Res. 2024; 60(1):e14376.

PMID: 39225454 PMC: 11782076. DOI: 10.1111/1475-6773.14376.


Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness.

Ladjevardi C, Koliadi A, Ryden V, El-Naggar A, Digkas E, Valachis A Front Oncol. 2024; 14:1399171.

PMID: 38988708 PMC: 11233440. DOI: 10.3389/fonc.2024.1399171.


Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.

Spierer R, Lavi I, Bloch S, Mazar M, Golan D J Neurol. 2023; 270(10):4632-4639.

PMID: 37589743 DOI: 10.1007/s00415-023-11935-4.


References
1.
Tsujii M, Kawano S, DuBois R . Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997; 94(7):3336-40. PMC: 20370. DOI: 10.1073/pnas.94.7.3336. View

2.
Cuzick J, Otto F, Baron J, Brown P, Burn J, Greenwald P . Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009; 10(5):501-7. DOI: 10.1016/S1470-2045(09)70035-X. View

3.
Ridker P, Cook N, Lee I, Gordon D, Gaziano J, Manson J . A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352(13):1293-304. DOI: 10.1056/NEJMoa050613. View

4.
Han E, Jang S, Kim G, Lee Y, Choe E, Nam C . Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. Medicine (Baltimore). 2016; 95(6):e2786. PMC: 4753931. DOI: 10.1097/MD.0000000000002786. View

5.
Berger J, Roncaglioni M, Avanzini F, Pangrazzi I, Tognoni G, Brown D . Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006; 295(3):306-13. DOI: 10.1001/jama.295.3.306. View